# Molecular Immunology and Tumor Biology

> **NIH NIH T32** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $480,327

## Abstract

ABSTRACT
This T32 Training Grant has for nearly four decades focused on the successful training
of research-oriented pathologist-scientists in the Department of Pathology at the
Massachusetts General Hospital. Over the past two five-year funding periods, trainees
have published a considerable number of papers, including many in high quality
journals, and have competed successfully for faculty positions in prestigious universities
and medical schools and for research-focused positions in industry. The mentors of this
current proposal comprise 32 Harvard and Massachusetts Institute of Technology faculty
who are primarily centered in the Department of Pathology and Cancer Center at the
Massachusetts General Hospital. This interactive community of fundamental researchers
and physician-scientists is organized into thematic programs that include: cancer
genetics; computational biology and bioinformatics; immunology and immunotherapy; in
vivo imaging for cancer biology and diagnostics; chemical and functional genomics;
epigenetics; cell cycle control and DNA damage; animal models of cancer; tissue, cell,
and genome engineering; and single cell cancer genomics. As in previous cycles, the
trainees will be selected from a highly competitive pool of M.D., M.D-Ph.D. and Ph.D.
applicants on the basis of prior academic and research achievements and evidence of a
strong commitment to a career in cancer biology. The period of training will be two or
three years for each successful applicant. An active and program-specific recruitment
and retention program to enhance diversity ensures that diverse applicants have access
to, and will succeed in, the training program. In summary, the proposed T32 program
renewal capitalizes on a highly interactive, experienced and focused faculty; a
distinguished record of training productive physicians and scientists, including
underrepresented minorities; state-of-the-art facilities and educational resources; and
exposure of the trainees to basic and translational aspects of cancer biology.

## Key facts

- **NIH application ID:** 10172499
- **Project number:** 2T32CA009216-41
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** David Michael Langenau
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $480,327
- **Award type:** 2
- **Project period:** 1978-09-30 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10172499

## Citation

> US National Institutes of Health, RePORTER application 10172499, Molecular Immunology and Tumor Biology (2T32CA009216-41). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10172499. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*